Abstract: The invention relates to sulfated glycosaminoglycanoid derivatives of the heparin and heparin sulfate type, of which N-sulfate, N-acetate, and hydroxy groups, are replaced by alkoxy, aryloxy, aralkoxy, or O-sulfate groups. The compounds have antithrombotic and smooth muscle cell proliferation inhibiting activities.

Abstract: A novel blend composition comprising one or more cationic polysaccharides and one or more anionic polysaccharides is provided. The blend is capable of producing enhanced viscosities when distributed in a solvent. The blend is suitable for use in foods, explosives, oil field chemicals, textile fibers, paper production, personal care products, agricultural chemicals and cosmetics.

Abstract: A glucofuranose derivative substituted at the 3,5,6- or 3,6-positions with a radical that provides an anionic charge at physiological pH values is disclosed, as are pharmaceutical compositions, and methods of making and using the same. The compounds are useful in treating inflammation, and particularly conditions that involve neutrophil influx; they are also useful in inhibiting gastric ulcer formation.

Abstract: The present invention provides N- and O-substituted aminophenol derivatives of the general formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, G and L are as hereinbefore defined. The present invention also provides intermediates for the preparation of these aminophenol derivatives of general formula (I), as well as the use of the aminophenol derivatives of general formula (I) for the determination of hydrolyses, as well as for the preparation of agents for carrying out determinations of hydrolyses.

Abstract: Pharmaceutical compositions in the form of stable sucralfate suspensions free of suspending agents, wherein the sucralfate is present in the form of a gel having self-suspending properties and is suspended in an aqueous carbohydrate solution in a quantity of between 1 and 40% of sucralfate by weight.Said gel has a surface area exceeding 200 m.sup.2 /g and is prepared by dissolving powdered sucralfate in an HCl solution and then precipitating it with an NaOH solution added to a pH of between 4 and 4.5.

Abstract: The invention relates to sulphated polysaccharides obtained from fucuses extracted from pheophyceae. The molecular weight of these polysaccharides is greater than 5 and less than 40 Kda; their sulphur content is greater than that of the original fucus and they contain less than 0.15% of contaminant proteins. Applications as anticoagulant and anticomplementary agents.

Abstract: Sulphated O-Polysaccharide-trehaloses which can be used as medicaments, especially for the treatment of arteriosclerotic disorders.

Abstract: The diosmin heptakis (hydrogensulfate) aluminum complex is described, as l as its preparation procedure, characterized by reacting one mole of diosmin with seven moles of a sulfating agent in a dry medium and treatment with an aqueous aluminum hydroxycloride solution of the diosmin heptakis (hydrogensulfate) sodium salt thus obtained. A description of pharmacological assays carried out to confirm the cytoprotective action of the product is included.

Abstract: An acid heteropolysaccharide P-318 which comprises galactose, galacturonic acid, N-acetylfucosamine and pyruvic acid in a ratio of about 2:3:1:1, a sulfated heteropolysaccharide P-318 having a 10% or less sulfur content which is prepared by sulfating said acid heteropolysaccharide and a process for preparing an acid heteropolysaccharide P-318 which comprises culturing Pseudomonas sp. 318 to produce the acid heteropolysaccharide P-318 and collecting the thus produced acid heteropolysaccharide P-318. The sulfated polysaccharide P-318 of the invention shows a strong antiviral activity in spite of a lower content of sulfate.

Abstract: Complexes of sucralfate with alpha cyclodextrin, beta cyclodextrin, gamma cyclodextrin or 2-hydroxypropyl beta cyclodextrin are disclosed. Also disclosed are a process for producing complexes and compositions and a method for reducing gastric injury, employing the complexes.

Abstract: Sulfated tannins or salts thereof are herein disclosed. These compounds can be prepared by a method which comprises reacting tannin with a sulfonating agent under a basic condition. These compounds show antiviral activity and reverse transcriptase inhibitor, effects and can be used to treat patients infected with a variety of virus such as AIDS virus, herpesvirus, influenza virus or rhinovirus.

Abstract: Dextran sulfate, .beta.-1,3-glucan sulfate, and the salts thereof are angiostatic and useful for treatment and prevention of various diseases caused by abnormally accelerated angiogenesis. Combination of such a compound with a steroidal or non-steroidal substance increases the angiostatic activity of each compound to induce the combined effect.

Abstract: Novel phenylazonaphthol derivatives, e.g., 4-(4'-nitro-2'-sulfophenylazo)-1-naphthyl-N-acetyl-.beta.-D-glucosaminide sodium salt, are excellent substrates for determining N-acetyl-.beta.-D-glucosaminidase (NAG) activity in urine collected from the patient with renal disorders. The substrate has high water solubility, is not affected by interferences in urine and provides a simple method for determination of NAG activity which is suited for both rate and endpoint assays.

Abstract: A glucofuranose derivative substituted at the 3,5,6- or 3,6-positions with a radical that provides an anionic charge at physiological pH values is disclosed, as are pharmaceutical compositions, and methods of making and using the same. The compounds are useful in treating inflammation, and particularly conditions that involve neutrophil influx; they are also useful in inhibiting peptic ulcer formation.

Abstract: A sucralfate-like chemical compound which is free flowing but turns viscid upon contact with acid or non-acid aqueous liquid. The compound is prepared by adding an excess of aluminum chlorohydrate to sucrose octaammonium sulfate in aqueous alcohols.

Abstract: A novel 3-sulfatoglucuronic acid-containing compound is produced. A method for antibody removal from a liquid sample, and a method of treatment for antibody-related disorders is disclosed, along with a diagnostic kit.

Abstract: The present invention provides compounds of the general formula ##STR1## wherein R.sub.1 is a hydrogen atom, a methyl, ethyl, propyl, isopropyl, butyl, tert. butyl or 1-alkoxyalkyl radical or an optionally hydrophilically substituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, tetrahydropyranyl, piperidinyl, N-methyl substituted piperidinyl or N-ethyl substituted piperidinyl, pyridinyl, thiophenyl or 1,1-dioxo-tetra- hydrothiopyranyl radical or an amino group which is optionally substituted by the same or different substituents selected from methyl, ethyl, propyl and isopropyl radicals. R.sub.2 is an oligoglucoside residue with 2, 3 or 4 glucose units and X is a hydrogen atom or an optically determinable residue. The present invention also provides processes for the preparation of compounds (I) and reagents for the determination of .alpha.-amylase containing them. Furthermore, the present invention provides a process for the determination of .alpha.

Abstract: This invention encompasses a method and compositions which inhibit pancreatic cholesterol esterase and triglyceride lipase and hence, lower cholesterol and triglycerides in the blood stream.

Abstract: This invention relates to novel compounds which are precursors for di- and triarylmethane dye precursor compounds possessing a thiolactone, dithiolactone or thioether ring-closing moiety.

Abstract: A modified cellulose has a structure represented by the formula ##STR1## Cell is the framework of the unmodified cellulose molecule or of the chitin molecule, in each case without hydroxyl groups. Z is a nitrogen or sulfur atom. In the case where Z is a nitrogen atom, T and Z together are an acylamide or urea group and Q is (X'-Y') and/or together with the O an ester group and/or together with the O a carbamate group. In the case where Z is a sulfur atom, T is omitted and Q together with the O is an ester group and/or together with the O a carbamate group and, as desired, (X'--Y'). The relationships 0<n<m and 0.ltoreq.s<m are obeyed and (n+s) indicates the mean degree of substitution. m=3 in the case of the unmodified cellulose molecule and m=2 in the case of the chitin molecule.

Abstract: The invention relates to polysulfuric acid esters of bis-aldonamides in which the underlying aldonic acids can be linked glycosidically with a galactopyranosyl, mannopyranosyl, glucopyranosyl or oligopyranosyl radical in the 3-, 4- or 6-position. They are therapeutically active compounds, whose preparation and pharmaceutical compositions are likewise described.

Abstract: Sucralfate is prepared in good yields and in newly useful form first by reacting sucrose with chlorosulfonic acid in 2-picoline. The amonium salt is then formed and reacted with aluminum chlorohydrate in specific sequence and alcoholic solvent. The two distinct products have unexpected pharmaceutical and physical characteristics. The oral liquid suspensions also must be critically formulated.

Abstract: A second-step virus binding receptor is found in nature on the surface of animal and plant cells. This receptor is thought to be needed for virus penetration into target cells. The second-step receptor has been found to bind a wide variety of viruses belonging to a number of different families. The second-step receptor and natural or synthetic substances which correspond to or are analogous to the binding epitope of the second-step receptor in that they are able to bind to a site on the virus which recognizes the binding epitope of the natural second-step receptor, are therefore indicated for the diagnosis, prophylaxis or treatment of viral infections.

Abstract: An alkyloligoglycoside having an alkyl group content of 8 to 22 carbon atoms and having an average degree of oligomerization of 1 to 5 is sulfated with a sulfating agent in an organic solvent having a boiling point of 30.degree. to 100.degree. C.

Abstract: The invention relates to the use of selected carboxylic acid esters which are liquid under reaction conditions and correspond to general formula (I)X--COOR.sup.1 (I)in which R.sup.1 is an alkyl radical unbranched in the .alpha.-position and X is hydrogen or a group corresponding to general formula (II) ##STR1## in which R.sup.2, R.sup.3 and R.sup.4 represent fluorine and/or chlorine and one of these substituents may also be hydrogen or one or two of these substituents may also be lower alkyl, as reaction medium for the sulfonation and/or sulfatization or organic components with SO.sub.3 to light-colored reaction products.

Abstract: Bismuth salts of phosphorylated and/or sulfonated saccharides are prepared from a corresponding metal salt reactant, a water soluble organic acid, and a bismuth substance. For example, a complex salt of bismuth hydroxide sucrose octasulfate can be prepared in high yield and good purity from potassium sucrose octasulfate, trichloroacetic acid, trifluoracetic acid or 4-methylbenzenesulfonic acid, and bismuth hydroxide. Corresponding hydrogen phosphorylated and/or sulfonated saccharides may be intermediate products.

Abstract: Process for the depolymerization and sulfation of polysaccharides by reaction of said polysaccharides with a sulfuric acid/chlorosulfonic acid mixture.

Abstract: Bismuth salts of phosphorylated and/or sulfonated saccharides can be prepared in one reaction vessel from a corresponding metal salt reactant, a water soluble organic acid, and a bismuth substance. For example, a complex salt of bismuth hydroxide sucrose octasulfate can be prepared in high yield and good purity from potassium sucrose octasulfate, trifluoracetic acid, and bismuth hydroxide.

Abstract: Sialic acid derivatives and process for preparing these compounds. In these compounds, a phenylthio group is stereo-selectively incorporated at the 3-position of the sialic acid. These compounds are useful as intermediates for synthesizing various glycosides such as ganglioside, a blood type determining factor, GQ.sub.1b etc. The present invention also relates to sialic acid-containing oligosaccharide derivatives and process for preparing them.

Abstract: This invention relates to glucopyranose compounds of formula (I) and (IA) ##STR1## and the non-toxic salts thereof wherein the substituents are as defined herein. Such materials possess enhancing activity of cellular immunity (e.g. mitogenic activity) to living tissue and therefore are useful as anti-tumor agents.

Abstract: There is disclosed oligosaccharide compounds having heparin-like anticomplement activity and reduced anticoagulant activity as compared with heparin on a weight or molar basis. The oligosaccharide compounds have at least 5 and no greater than 25 saccharide units. The oligosaccharides can have an even nuber of saccharide units with a terminus nonreducing sugar, or an odd number of saccharide units without a terminus nonreducing sugar. There is also disclosed anticomplement pharmaceutical compositions with reduced anticoagulant side effect activity and a process for preparing the oligosaccharide compounds.

Abstract: The invention refers to the preparation of diosmin octakis (hydrogen sulfate) aluminum complex, a new derivative of diosmin, by reaction of diosmin with a sulfating agent, such as sulfur trioxide-pyridine complex, sulfur trioxide-trimethylamine complex and sulfur trioxide-triethylamine complex, at a temperature between 40.degree. and 110.degree. C., in an appropriate medium, with preference pyridine, dimethylformamide and dimethylacetamide, and final addition of aluminum hydroxychloride.

Abstract: Novel compounds with anti-proliferative and mucosaprotective activity are obtained by sulfating trestatins.

Abstract: A second-step virus binding receptor is found in nature on the surface of animal and plant cells. This receptor is thought to be needed for virus penetration into target cells. The second-step receptor has been found to bind a wide variety of viruses belonging to a number of different families. The second-step receptor and natural or synthetic substances which correspond to or are analogous to the binding epitope of the second-step receptor in that they are able to bind to a site on the virus which recognizes the binding epitope of the natural second-step receptor, are therefore indicated for the diagnosis, prophylaxis or treatment of viral infections.

Abstract: The present invention is dealing with new pentasaccharides of the formula I: ##STR1## These pentasaccharides have anti-thrombotic activity and especially they possess potent anti-Xa activity, inactivate thrombin via HC-II, but do not inactivate thrombin via AT-III.The invention also refers to new tetrasaccharides which may be used as intermediates in the synthesis of the above pentasaccharides.

Abstract: The invention relates to a process for the organic synthesis of oligosaccharides constituting or comprising fragments of acid mucopolysaccharides comprising the reaction of two compounds constituted or terminated by units of glucosamine structure and of uronic acid structure respectively, said units being specifically substituted. This process particularly enables valuable anticoagulant drugs to be obtained.

Abstract: A new method for preparation of sulfated polysaccharides by means of pyridine-chlorosulfonic acid reagents. The polysaccharide is before sulfation treated with a reducing agent, e.g. sodium borohydride.

Abstract: 1,4.alpha.disaccharides of formula: ##STR1## with Z representing a nitrogenous functional group,M hydrogen or a sulphate or acetyl group,R an alkyl radical of 1 to 4 carbon atoms andA functional group such as an acid group, or a derivative.

Abstract: The present invention relates to novel xylan sulfates of average molecular weight comprised between 2000 and 5000 Daltons.The invention also relates to their process of preparation by fractionation and their use in therapeutics as orally active antithrombotic and hypolipaemic agents.

Abstract: This invention relates to new xylane sulfates having an apparent molar weight comprised between 7000 and 12000.This invention relates also to a process for their preparation by fractionation, and to the therapeutic application thereof as anti-thrombosis and hypolipemic agents.

Abstract: A lipoprotein adsorbent for use in extracorporeal circulation treatment which is made of a water-insoluble porous hard gel which has an exclusion limit value from 10.sup.6 to 10.sup.9 measured by using glubular proteins and comprises a polymer having hydroxy group in at least a part of the molecule, at least a part of hydroxy groups on the surface of said gel being converted to sulfates. By using the adsorbent of the present invention, LDL and VLDL can be selectively and effectively removed from the body fluids of the patient. Further, the adsorbent of the present invention can be prepared in a lower cost than the adsorbent based on the principle of the affinity chromatography, in which a relatively expensive ligand is employed.

Abstract: Compounds of the formula ##STR1## wherein X is halogen; each R independently represents H, a C.sub.1 -C.sub.4 alkyl group, a C.sub.2 -C.sub.4 alkanoyl group, a phosphate group, or a sulfate, sulfonate, or benzoate group with the proviso that no more than one sulfate, sulfonate, or benzoate group is present in said compound; and R' represents R or a carbohydrate residue derived from a carbohydrate having the formula R'OH with the proviso that R' and the R on C-2 or both R groups on C-3 and C-4 together can represent an isopropylidene group; or a pharmaceutically acceptable salt thereof, are disclosed along with methods of synthesizing and using these compounds.

Abstract: A lipoprotein adsorbent for use in extracorporeal circulation treatment which is made of a water-insoluble porous hard gel which has an exclusion limit value from 10.sup.6 to 10.sup.9 measured by using glubular proteins and comprises a polymer having hydroxy group in at least a part of the molecule, at least a part of hydroxy groups on the surface of said gel being converted to sulfates. By using the adsorbent of the present invention, LDL and VLDL can be selectively and effectively removed from the body fluids of the patient. Further, the adsorbent of the present invention can be prepared in a lower cost than the adsorbent based on the principle of the affinity chromatography, in which a relatively expensive ligand is employed.

Abstract: The administration of "active" chondroitin sulfate A (CSA), "active" chondroitin sulfate C (CSC), or mixtures thereof to mammals including humans suffering from cancer, bacterial infections, trauma, irritation, placement of foreign objects, tubes or instruments, or damage of the upper or lower urinary tract, and related transitional cell surfaces to prevent cancer cell implantation or adherence, bacterial infestation or adherence, trauma, irritation, or damage from placement of foreign objects, tubes or instruments in the kidney, renal pelvis, ureter, bladder, urethra and related transitional cell surfaces by the irrigation of said surfaces and/or tubes and instruments with a solution of said drugs or mixtures thereof.

Abstract: Damage to endothelial and epithelial cells subject to trauma can be substantially reduced by using a wafer of a viscoelastic material. This method is particularly useful when applied prior to ophthalic surgery, particularly intraocular lens implantation surgery. Lens implantation is facilitated by the compression of lens haptics by this delivery system.

Abstract: Process for producing 1-halo-2-deoxy-2-fluoroarabinofuranoside derivatives bearing protective ester groups from 1,3,5-tri-O-acylribofuranose; the 1-halo compounds are intermediates in the synthesis of therapeutically active nucleosidic compounds.

Abstract: 1,4 .alpha. disaccharides of formula: ##STR1## with Z representing a nitrogenous functional group,M hydrogen or a sulphate or acetyl group,R an alkyl radical of 1 to 4 carbon atoms andA a functional group such as an acid group, or a derivative.

Abstract: The invention relates to a process for the preparation of an injectable chondroitin polysulfate, which is characterized in thatA crude chondroitin polysulfate is depolymerized oxidatively,B the depolymerized chondroitin polysulfate is bleached, if necessary, with peracetic acid,C the product obtained after A or B is subjected once or twice to precipitation with methanol and/or ultrafiltration for fractionation with respect to molecular weight,D the product obtained after C is demineralized, if necessary, with cation exchangers, andE the product obtained after C or D is decolorized, if necessary, with active charcoal.The invention furthermore relates to a chondroitin polysulfate which can be prepared by the above process. The invention also relates to a chondroitin polysulfate with an acute toxicity (LD.sub.50), on intravenous administration, of >3,500 mg/kg in NMRI mice, of >3,000 mg/kg in Wistar rats, of >1,000 mg/kg in cats and of >1,000 mg/kg in dogs.

Abstract: Cation salts of substituted phenyl-1-thio(poly-O-sulfo)-.alpha.(or .beta.)-D-glucopyranoside, useful as modulators of the complement system, the intermediates thereof and the process of making such intermediates and end products.

Abstract: A chondroitin or a chondroitin sulfate covalently or ionically bonded to a drug substance of the group consisting of chloramphenicol, methotrexate, adriamycin, vinblastine, vincristine, vindesine, 6-mercaptopurine, 5-fluorouracil, the penicillin antibiotics, the cephalosporin antibiotics, and the 1-oxacephalosporin antibiotics to form a prodrug which, when injected into animal tissue, undergoes natural conversion in the physiological environment to provide controlled release of the drug or an active drug complex.